You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Harvesting specific plant metabolites from hairy root cultures using magnetized n

    SBC: NAPROGENIX, INC.            Topic: NCCIH

    DESCRIPTION: Plants produce a wide variety of valuable bioactive metabolites, but these are commonly present in low concentrations in the wild-type plant. This makes the separation and purification of these compounds complicated and expensive. The applicant company, Naprogenix Inc, has developed a technology for increasing the yields of specific bioactive metabolites in mutant plant cell cultures ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Small Molecule Therapeutics for Pancreatic Cancer

    SBC: ChemRegen Inc            Topic: NCI

    Project Summary/Abstract Developing new ways to treat pancreatic cancer is a significant challenge. Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and results in an estimated 37,000 deaths/year. Pancreatic cancer therapeutic options are limited to surgery and/or combinations of chemotherapy and radiation. Unfortunately, late-stage diagnosis of pancreat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Ex vivo purging strategy for treatment of multiple myeloma

    SBC: Dnatrix, Inc            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this application is to develop a novel ex vivo purging method using myxoma virus (MYXV), a rabbit-specific poxvirus, to improve the clinical outcomes in treatment of multiple myeloma (MM). MM is aclonal plasma cell malignancy that has to date resisted essentially all therapeutic strategies. Currently, the standard of care for patients wit ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. ChemoFilter: A Novel Catheter Device to Enable High-Dose Chemotherapy Treatment

    SBC: CHEMOFILTER, INC.            Topic: NCI

    Project Summary: Intravenous dosing of drugs for applications ranging from cancer chemotherapy to anti-microbials to lytic (blood clot dissolving) agents is limited by systemic toxicity. Currently, the only ways to remove drugs from the blood are throughnatural metabolism or costly impractical measures such as dialysis. Despite intense focus on targeted drug delivery agents, these therapies are c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Novel Therapies for Treating Breast-Cancer-Related Lymphedema

    SBC: ADEPTHERA, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Destruction of lymphatic vessels during the treatment of breast cancer by surgery and/or radiation therapy can lead to the development of secondary lymphedema. The breast-cancer-related lymphedema is associated with debilitating limb swelling, chronic inflammation, tissue fibrosis, and increased susceptibility to infection. It has been estimated that approximat ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Intra-procedure Deformable Ultrasound-MRI Fusion for Prostate Biopsies

    SBC: ZMK Medical Technologies, Inc.            Topic: NCI

    This proposal is a collaborative effort between Yale University and the medical device company Eigen to develop a more robust and accurate method for the deformable fusion of pre-operative magnetic resonance images (MRI) and intra-procedure trans-rectal ultrasound (TRUS) images to guide prostate biopsy. Prostate cancer is a major cause of death in the U.S. and biopsy is the gold-standard for its d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Validation of a Novel Treatment for Glioblastoma

    SBC: CURTANA PHARMACEUTICALS, INC.            Topic: NCI

    ? DESCRIPTION (provided by applicant): The goal of this application is to study in vivo efficacy of CT102, a newly discovered inhibitor of the OLIG2 transcription factor in animal models of glioblastoma (GBM), a highly underserved area of pharmacotherapy. In this proposal, the experienced drug discovery group at Curtana Pharmaceuticals Inc. will conduct a pre-clinical evaluation of selectivity ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting of Myc-Max dimerization for the treatment of cancer

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Myc is a key transcriptional regulator due to its critical role in many fundamental cellular processes, such as cell cycle progression and cell growth. Therefore, dysregulation of Myc expression can lead to disease, including cancer. Myc is overexpressed in many human tumors, and it is estimated that 1 in 7 cancer deaths in the United States are resultant of hi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Identification and Quantification of Sequence Specific RNA Modifications via the Alpha-Hemolysin Latch Zone

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): During this STTR program, Electronic BioSciences (EBS) proposes to develop a nanopore based system around our University of Utah collaborators newly developed technology that will be capable of identifying and quantifying sequence specific RNA modifications. A system capable of quantitative, low cost, high throughput, RNA modification characterization has the c ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Mitochondrial Uncoupling as a Therapeutic Target in Obesity

    SBC: Nano-Mite Technologies, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity is recognized as a national and global epidemic, as approximately 65% of adults in the United States are classified as overweight or obese as defined by body mass index (BMI). In fact, in the year 2000, the human race reached a historical landmark, when for the first time in history the number of adults with excess weight surpassed the number of those w ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government